CVS HEALTH Corp CVS
Last close
96.74
2026-09-04
Market cap
$123.73B
2026-06-30 share count
52-week range
69.51 - 110.68
Valuation FY2025 figures against the last close
P/S0.3x
P/E69.6x
P/FCF15.8x
EV/EBITDA12.2x
Dividend yield2.7%
Diluted EPS1.39
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $402.07B | $372.81B | $357.78B | $322.47B | $292.11B | $268.71B | $256.78B | $194.58B | $184.79B | $177.53B |
| Cost of revenue | $221.17B | $206.29B | $217.10B | $196.89B | $175.80B | $163.98B | $158.72B | $156.45B | $153.45B | $146.53B |
| Gross profit | $180.90B | $166.52B | $140.68B | $125.58B | $116.31B | $104.72B | $98.06B | $38.13B | $28.55B | $28.86B |
| Total operating expenses | $397.41B | $364.29B | $344.03B | $314.51B | $278.80B | $254.79B | $244.79B | $190.56B | $18.81B | $18.45B |
| Operating income | $4.66B | $8.52B | $13.74B | $7.95B | $13.31B | $13.91B | $11.99B | $4.02B | $9.54B | $10.39B |
| Interest expense | $3.12B | $2.96B | $2.66B | $2.29B | $2.50B | $2.91B | $3.04B | $2.62B | $1.06B | $1.08B |
| Pre-tax income | $2.14B | $6.15B | $11.17B | $5.84B | $10.54B | $9.77B | $9.00B | $1.41B | $8.27B | $8.64B |
| Income tax | $408.0M | $1.56B | $2.81B | $1.51B | $2.55B | $2.57B | $2.37B | $2.00B | $1.64B | $3.32B |
| Net income | $1.77B | $4.61B | $8.34B | $4.31B | $8.00B | $7.18B | $6.63B | -$594.0M | $6.62B | $5.32B |
| EPS, basic | 1.40 | 3.67 | 6.49 | 3.29 | 6.07 | 5.48 | 5.10 | -0.57 | 6.47 | 4.93 |
| EPS, diluted | 1.39 | 3.66 | 6.47 | 3.26 | 6.02 | 5.46 | 5.08 | -0.57 | 6.44 | 4.90 |
| Shares, diluted (wtd. avg.) | $1.27B | $1.26B | $1.29B | $1.32B | $1.33B | $1.31B | $1.30B | $1.04B | $1.02B | $1.08B |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $8.45B | $8.59B | $8.20B | $13.30B | $12.69B | $11.04B | $8.41B | $6.55B | $1.90B | $3.52B |
| Short-term investments | $2.15B | $2.41B | $3.26B | $2.78B | $3.12B | $3.00B | $2.37B | $2.52B | $111.0M | $87.0M |
| Receivables | $39.78B | $36.47B | $35.23B | $27.28B | $24.43B | $21.74B | $19.62B | $17.63B | $13.18B | $12.16B |
| Inventory | $19.25B | $18.11B | $18.02B | $19.09B | $17.76B | $18.50B | $17.52B | $16.45B | $15.30B | $14.76B |
| Total current assets | $74.71B | $68.64B | $67.86B | $65.63B | $60.01B | $56.37B | $50.30B | $45.24B | $31.23B | $31.04B |
| Property, plant and equipment | — | — | — | $12.87B | $12.90B | $12.61B | $12.04B | $11.35B | $10.29B | $10.18B |
| Goodwill | $85.48B | $91.27B | $91.27B | $78.15B | $79.12B | $79.55B | $79.75B | $78.68B | $38.45B | $38.25B |
| Other intangibles | $25.51B | $27.32B | $29.23B | $24.80B | $29.03B | $31.14B | $33.12B | $36.52B | $13.63B | $13.51B |
| Total assets | $253.54B | $253.22B | $249.73B | $228.28B | $233.00B | $230.72B | $222.45B | $196.46B | $95.13B | $94.46B |
| Accounts payable | — | — | — | — | — | — | — | — | $8.86B | $7.95B |
| Short-term debt | $0 | $2.12B | $200.0M | $0 | — | — | $3.78B | $1.26B | $3.54B | $42.0M |
| Total current liabilities | $88.69B | $84.61B | $79.19B | $69.42B | $67.81B | $62.02B | $53.30B | $44.01B | $30.65B | $26.25B |
| Long-term debt | — | — | — | — | — | — | — | $71.44B | $22.18B | $25.61B |
| Total liabilities | $178.16B | $177.49B | $173.09B | $156.51B | $157.62B | $161.01B | $158.28B | $137.91B | $57.44B | — |
| Retained earnings | $61.20B | $62.84B | $61.60B | $56.40B | $54.91B | $49.64B | $45.11B | $40.91B | $43.56B | $38.98B |
| Total equity | $75.21B | $75.56B | $76.64B | $71.77B | $74.84B | $69.70B | $64.17B | $58.54B | $37.70B | $36.83B |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $10.64B | $9.11B | $13.43B | $16.18B | $18.27B | $15.87B | $12.85B | $8.87B | $8.01B | $10.14B |
| Depreciation and amortisation | $4.61B | $4.60B | $4.37B | $4.22B | $4.49B | $4.44B | $4.37B | $2.72B | $2.48B | $2.48B |
| Stock-based compensation | $535.0M | $540.0M | $588.0M | $447.0M | $484.0M | $400.0M | $453.0M | $280.0M | $234.0M | $222.0M |
| Capital expenditure | $2.83B | $2.78B | $3.03B | $2.73B | $2.52B | $2.44B | $2.46B | $2.04B | $1.92B | $2.22B |
| Investing cash flow | -$5.87B | -$7.61B | -$20.89B | -$5.05B | -$5.26B | -$5.53B | -$3.34B | -$43.28B | -$2.88B | -$2.47B |
| Financing cash flow | -$4.94B | -$1.14B | $2.68B | -$10.52B | -$11.36B | -$7.70B | -$7.65B | $36.82B | -$6.75B | -$6.76B |
| Dividends paid | $3.40B | $3.37B | $3.13B | $2.91B | $2.62B | $2.62B | $2.60B | $2.04B | $2.05B | $1.84B |
| Buybacks | $0 | $3.02B | $2.01B | $3.50B | $0 | $0 | $0 | $0 | $4.36B | $4.46B |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0000064803-26-000010.
Others in SIC 5912
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| PETS | PETMED EXPRESS INC | $39.2M | — | -21.1% |
| YI | 111, Inc. | — | — | -9.0% |
| GRDN | Guardian Pharmacy Services, Inc. | — | — | 17.9% |
| RDGT | Ridgetech Inc. | — | — | 10.2% |